Abstract

Antimalarials (AMs) are one of the oldest medications used to treat human disease and one of the first and safest disease-modifying antirheumatic drugs. Several factors have favored the wide use of AMs in systemic lupus erythematosus (SLE). First, there is convincing evidence that they are effective. Second, there are enough data showing that continuous use of AMs leads to better outcomes, prevents damage accrual, and improves survival. Third, effective retinal monitoring strategies to identify early and reversible retinal changes are currently available.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call